HALO - Halozyme Therapeutics EPS beats by $0.05 misses on revenue August, 06 2019 04:04 PM Halozyme Therapeutics Inc. Halozyme Therapeutics (NASDAQ:HALO): Q2 GAAP EPS of -$0.10 beats by $0.05.More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...